EA199700425A1 - DERIVATIVES OF PIPERAZINE - Google Patents

DERIVATIVES OF PIPERAZINE

Info

Publication number
EA199700425A1
EA199700425A1 EA199700425A EA199700425A EA199700425A1 EA 199700425 A1 EA199700425 A1 EA 199700425A1 EA 199700425 A EA199700425 A EA 199700425A EA 199700425 A EA199700425 A EA 199700425A EA 199700425 A1 EA199700425 A1 EA 199700425A1
Authority
EA
Eurasian Patent Office
Prior art keywords
piperazine
derivatives
carbamoylmethyl
indol
ylmethyl
Prior art date
Application number
EA199700425A
Other languages
Russian (ru)
Other versions
EA000669B1 (en
Inventor
Масааки Мацуда
Дайдзиро Хагивара
Такаси Манабе
Нобукийо Кониси
Синдзи Сигенага
Кендзи Мурано
Хироси МАЦУДА
Хироси Мияке
Original Assignee
Фудзисава Фармасьютикал Ко., Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фудзисава Фармасьютикал Ко., Лтд filed Critical Фудзисава Фармасьютикал Ко., Лтд
Publication of EA199700425A1 publication Critical patent/EA199700425A1/en
Publication of EA000669B1 publication Critical patent/EA000669B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Данное изобретение касается (2R)-1-[3,5-бис-(трифторметил)бензоил]-2-(1Н-индол-3-илметил)-4-[N-(4-метил-1-пиперазинил)карбамоилметил]пиперазина или его соли фумаровой кислоты, способа его получения, включающей его фармацевтической композиции и его использования в качестве лекарственного препарата.Международная заявка была опубликована вместе с отчетом о международном поиске.This invention relates to (2R) -1- [3,5-bis- (trifluoromethyl) benzoyl] -2- (1H-indol-3-ylmethyl) -4- [N- (4-methyl-1-piperazinyl) carbamoylmethyl] piperazine or its fumaric acid salt, method of its production, including its pharmaceutical composition and its use as a drug. The international application was published together with an international search report.

EA199700425A 1995-05-25 1996-05-21 Piperazine derivatives EA000669B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45017695A 1995-05-25 1995-05-25
PCT/JP1996/001335 WO1996037489A1 (en) 1995-05-25 1996-05-21 1-benzoyl-2-(indolyl-3-alkyl)-piperazine derivatives as neurokinin receptor antagonists

Publications (2)

Publication Number Publication Date
EA199700425A1 true EA199700425A1 (en) 1998-12-24
EA000669B1 EA000669B1 (en) 2000-02-28

Family

ID=23787083

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199700425A EA000669B1 (en) 1995-05-25 1996-05-21 Piperazine derivatives

Country Status (14)

Country Link
EP (1) EP0846116A1 (en)
JP (1) JP3071829B2 (en)
KR (1) KR19990021857A (en)
CN (1) CN1072220C (en)
AU (1) AU706021B2 (en)
CA (1) CA2222041A1 (en)
EA (1) EA000669B1 (en)
HU (1) HUP9900822A3 (en)
IL (1) IL118369A (en)
NZ (1) NZ307625A (en)
TR (1) TR199600438A2 (en)
TW (1) TW391960B (en)
WO (1) WO1996037489A1 (en)
ZA (1) ZA964101B (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2189501A1 (en) * 1995-11-06 1997-05-07 Harry R. Howard Nk-1 receptor antagonists for the treatment of cancer
HUP9901037A3 (en) * 1995-12-18 2001-11-28 Fujisawa Pharmaceutical Co Piperazine derivatives,preparation and use thereof, pharmaceutical compositions containing these compounds
AUPO735997A0 (en) * 1997-06-17 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives
EP0899270B1 (en) * 1997-08-27 2008-05-21 Solvay Pharmaceuticals GmbH Indolylmethyl-N,N'-bisacylpiperazines as neurokinine receptor antagonists
DE19824865A1 (en) * 1997-08-27 1999-03-04 Solvay Pharm Gmbh New urea derivatives
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
DE10036818A1 (en) * 2000-07-28 2002-02-07 Solvay Pharm Gmbh New N-Triazolylmethyl-Piperazine Derivatives as Neurokinin Receptor Antagonists
UA75425C2 (en) 2001-07-09 2006-04-17 Piperazine oxime derivatives with antagonistic activity to nk-1 receptor, use thereof, a pharmaceutical composition based thereon, a method for producing and a method for producing intermediary compounds
UA77515C2 (en) 2002-04-04 2006-12-15 Diazabicyclo alkane derivatives possessing neuroldnin-nk1 receptor antagonistic activity
KR101412339B1 (en) 2004-07-15 2014-06-25 알바니 몰레큘라 리써치, 인크. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
US7956050B2 (en) 2005-07-15 2011-06-07 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
EP1940842B1 (en) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2008039327A2 (en) 2006-09-22 2008-04-03 Merck & Co., Inc. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
PL2336120T3 (en) 2007-01-10 2014-12-31 Msd Italia Srl Combinations containing amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
CA2676357A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1
US8106086B2 (en) 2007-04-02 2012-01-31 Msd K.K. Indoledione derivative
WO2008147864A2 (en) * 2007-05-22 2008-12-04 Xenon Pharmaceuticals Inc. Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions
CA2690191C (en) 2007-06-27 2015-07-28 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
WO2009111354A2 (en) 2008-03-03 2009-09-11 Tiger Pharmatech Tyrosine kinase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
KR101830447B1 (en) 2009-05-12 2018-02-20 알바니 몰레큘라 리써치, 인크. 7-([1,2,4]TRIAZOLO[1,5-α]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
WO2010132487A1 (en) 2009-05-12 2010-11-18 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
US9034899B2 (en) 2009-05-12 2015-05-19 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
PE20121172A1 (en) 2009-10-14 2012-09-05 Merck Sharp & Dohme PIPERIDINS SUBSTITUTED WITH ACTIVITY IN HDM2
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
CA2805265A1 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
CA2807307C (en) 2010-08-17 2021-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP2632472B1 (en) 2010-10-29 2017-12-13 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
IN2013MN02170A (en) 2011-04-21 2015-06-12 Piramal Entpr Ltd
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP2844261B1 (en) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
MX363243B (en) 2012-11-28 2019-03-14 Merck Sharp & Dohme Compositions and methods for treating cancer.
BR112015013611A2 (en) 2012-12-20 2017-11-14 Merck Sharp & Dohme compound and pharmaceutical composition
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US20210277009A1 (en) 2018-08-07 2021-09-09 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69029231T2 (en) * 1989-02-10 1997-03-20 Otsuka Pharma Co Ltd INDOLDER DERIVATIVES, THEIR PRODUCTION AND THE MEDICINE CONTAINING THEM TO PREVENT AND TREAT NEPHRITIS
IL111730A (en) * 1993-11-29 1998-12-06 Fujisawa Pharmaceutical Co Piperazine derivatives processes for the preparation thereof and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
IL118369A0 (en) 1996-09-12
JPH11505830A (en) 1999-05-25
NZ307625A (en) 1999-02-25
HUP9900822A2 (en) 1999-06-28
AU5703196A (en) 1996-12-11
HUP9900822A3 (en) 1999-11-29
IL118369A (en) 2000-06-01
ZA964101B (en) 1996-07-29
TW391960B (en) 2000-06-01
AU706021B2 (en) 1999-06-03
WO1996037489A1 (en) 1996-11-28
TR199600438A2 (en) 1996-12-21
CN1072220C (en) 2001-10-03
EP0846116A1 (en) 1998-06-10
CA2222041A1 (en) 1996-11-28
KR19990021857A (en) 1999-03-25
CN1191533A (en) 1998-08-26
EA000669B1 (en) 2000-02-28
JP3071829B2 (en) 2000-07-31

Similar Documents

Publication Publication Date Title
EA199700425A1 (en) DERIVATIVES OF PIPERAZINE
BR9712085A (en) Heterocyclic metalloprotease inhibitors
EA200200571A1 (en) NEW COMPOSITION AND ITS APPLICATION
EA200200873A1 (en) NEW PIPERAZINE DERIVATIVES
EA200100002A1 (en) BENZOTIEPINES, possessing the activity of inhibitors of the displacement of bile acids in the podzvodushny gut and absorption of taurholy
EA199800290A1 (en) (METHYL SULFONIL) PHENYL-2- (5H) -FURANONES AS CYCLOOXYGENASE-2 INHIBITORS
EA199901063A1 (en) PIPERAZINE DERIVATIVES AND THEIR APPLICATION AS ANTI-INFLAMMATORY AGENTS
EA199800477A1 (en) QUINOLINE DERIVATIVES
EA200300248A1 (en) BICYCLOPIRASOLES, ACTIVE AS KINASE INHIBITORS, METHOD OF THEIR RECEIVING AND INCLUDING THEIR PHARMACEUTICAL COMPOSITIONS
RU2291860C3 (en) DERIVATIVES 2-OXO-1-PYRROLIDINE, METHOD FOR THEIR PRODUCTION AND APPLICATION
KR900012911A (en) Excitatory Amino Acid Receptor Antagonist Compound
EA200201271A1 (en) INHIBITORS 11-BETA-HYDROXYSTEROID DEGYDROGENASE TYPE 1
EA199900979A1 (en) COMPOSITIONS OF ACTIVATED PROTEIN
EA199700186A1 (en) NEW DIPEPTID AMIDINES USED AS THROMBIN INHIBITORS
RU95116357A (en) Derivatives of pyrrolidine and thiazolidine, method of their synthesis, method of enantiomers separation and pharmaceutical composition based on pyrrolidine and thiazolidine derivatives
EA200100958A1 (en) DERIVATIVES 4,5-DIARYL-3 (2H) -FURANONA AS INHIBITORS CYCLOOXYGENASE-2
FI963169A (en) Novel mercaptoacetylamido-1,3,4,5-tetrahydrobenz [c] azepin-3-one disulfide derivatives useful as enkephalinase and ACE inhibitors
DE69820632D1 (en) 2-PHENYL SUBSTITUTED 1- (N-PHENYLAMINOALKYL) PIPERAZINE DERIVATIVES
EA199800794A1 (en) NEW DERIVATIVES OF ARYL GLYCLILAMIDE, METHOD OF THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITION CONTAINING THESE CONNECTIONS
FI980862A (en) Chiral methylphenyl oxazolidinones
BR9714967B1 (en) ceftiofur-based pharmaceutical composition.
EA199900279A1 (en) DERIVATIVES OF BENZAMIDE AND THEIR APPLICATION AS MEDICINES WITH LTV4 ANTAGONISTIC ACTIVITY
ATE214275T1 (en) USE OF N-METHYL-N-((1S)-1-PHENYL-2-((3S)- 3-HYDROXYPYRROLIDINE-1-YL)-ETHYL)-2,2-DIPHENYL-ACETAMIDE HYDROCHLORIDE FOR THE PRODUCTION OF MEDICINAL PRODUCTS FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE
EA199900385A1 (en) COMPOUNDS 1-ARYL-2-ACYLAMINOETHANE AND THEIR APPLICATION AS ANTAGONISTS NEUROKININ, IN PARTICULAR NEUROKININ 1
EA199800721A1 (en) REHIVKULARIZATION INHIBITOR

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU